Taina Härkönen

Taina Härkönen

Auto-generated profile, based on publicly available information

Taina Härkönen

Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2012 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JNJanne K. Nieminen
Janne K. Nieminen
JVJukka Vakkila
Jukka Vakkila
HSHarri M. Salo
Harri M. Salo
NENina Ekstrom
Nina Ekstrom
THTaina Härkönen
Taina Härkönen
OVOuti Vaarala
Outi Vaarala
OBJECTIVE Dendritic cells (DCs) are largely responsible for the activation and fine-tuning of T-cell responses. Altered numbers of blood DCs have been reported in type 1 diabetes (T1D). We aimed at characterizing the less well-known phenotypic properties of DCs in T1D. RESEARCH DESIGN AND METHODS In a case-control setting, samples from a total of 90 children were studied by flow cytometry or by quantitative real-time PCR (qPCR). RESULTS We found decreased numbers of myeloid DCs (mDCs) (8.97 vs. 13.4 cells/μL, P = 0.009, n = 31) and plasmacytoid DCs (pDCs) (9.47 vs. 14.6 cells/μL, P = 0.018, n = 30) in recent-onset T1D. Using a panel of antibodies against functionally important DC markers, we detected a decreased expression of CC chemokine receptor 2 (CCR2) on mDCs (percentage above negative control, P = 0.002, n = 29) and pDCs (median intensity, P = 0.003, n = 30) from T1D patients. In an independent series of children, the reduced expression of CCR2 was confirmed by qPCR in isolated mDCs (P = 0.043, n = 20). Serum concentrations of CCR2 ligands monocyte chemotactic protein-1 and -3 did not differ between the groups. A trend for an enhanced responsiveness of the nuclear factor-κB pathway (P = 0.063, n = 39) was seen in mDCs from children with β-cell autoantibodies, which is possibly related to the reduced CCR2 expression, since CCR2 on mDCs was downregulated by nuclear factor-κB–activating agents. CONCLUSIONS Given the role of CCR2 in DC chemotaxis and in DC-elicited Th1 differentiation, our results may indicate a functionally important DC abnormality in T1D affecting the initiation and quality of immune responses.

10 January 2013 in Autoimmunity
Verified
Journal Article
Closed access
PDF file
MAMette K. Andersen
Mette K. Andersen
THTaina Härkönen
Taina Härkönen
CFCarol Forsblom
Carol Forsblom
PGPer-Henrik Groop
Per-Henrik Groop
MKMikael Knip
Mikael Knip
TTTiinamaija Tuomi
Tiinamaija Tuomi
Background and aims: Patients with type 1 diabetes have antibodies to ZnT8 protein is encoded by SLC30A8. The C-allele of the R325 W variant in SLC30A8 is associated with type 2 diabetes and reduced beta-cell function in non-diabetic subjects. Our aim was to assess the prevalence of ZnT8 autoantibodies (ZnT8A) in patients with adult-onset diabetes, and to characterize associations between ZnT8A and phenotype, as well as SLC30A8 and HLA-DQB1 genotypes. Methods: ZnT8A were analyzed in patients diagnosed with diabetes >35 years (type 1 diabetes: n = 274; Latent autoimmune diabetes in adults (LADA): n = 294). SLC30A8 R325 W (rs13266634) and HLA-DQB1 alleles were genotyped in all patients and 537 non-diabetic control subjects. Results: ZnT8A were significantly more prevalent in LADA (34.3%) compared to adult-onset type 1 diabetes (18.7%, p < 0.0001). Among the patients with adult-onset type 1 diabetes, ZnT8A were associated with shorter disease duration [4.4 (6.0) vs. 10.8 (11.2) years, p < 0.0001], whereas no such association was observed among patients with LADA. The SLC30A8 R325 W variant was associated with LADA with low GADA levels [SLC30A8 CC: OR (95% CI): 1.46 (1.00 – 2.13), p = 0.049], and reduced insulin secretion among the non-diabetic subjects and the patients with LADA. Conclusion: ZnT8A were more common and more persistent in patients with LADA compared to adult-onset type 1 diabetes, but their presence was not associated with specific phenotypic characteristics. The SLC30A8 CC genotype adds to the genetic heterogeneity of LADA linked to GADA reactivity.

19 February 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
HHHeikki Hyöty
Heikki Hyöty
SKSusanna Kääriäinen
Susanna Kääriäinen
JLJutta Laiho
Jutta Laiho
GCGail M. Comer
Gail M. Comer
WTWei Tian
Wei Tian
MSMiguel Sanjuan
Miguel Sanjuan
Aims/hypothesis: Infection with coxsackie B viruses (CVBs) can cause diseases ranging from mild common cold-type symptoms to severe life-threatening conditions. CVB infections are considered to be prime candidates for environmental triggers of type 1 diabetes. This, together with the significant disease burden of acute CVB infections and their association with chronic diseases other than diabetes, has prompted the development of human CVB vaccines. The current study evaluated the safety and immunogenicity of the first human vaccine designed against CVBs associated with type 1 diabetes in a double-blind randomised placebo-controlled Phase I trial. Methods: The main eligibility criteria for participants were good general health, age between 18 and 45 years, provision of written informed consent and willingness to comply with all trial procedures. Treatment allocation (PRV-101 or placebo) was based on a computer-generated randomisation schedule and people assessing the outcomes were masked to group assignment. In total, 32 participants (17 men, 15 women) aged 18–44 years were randomised to receive a low (n=12) or high (n=12) dose of a multivalent, formalin-inactivated vaccine including CVB serotypes 1–5 (PRV-101), or placebo (n=8), given by intramuscular injections at weeks 0, 4 and 8 at a single study site in Finland. The participants were followed for another 24 weeks. Safety and tolerability were the primary endpoints. Anti-CVB IgG and virus-neutralising titres were analysed using an ELISA and neutralising plaque reduction assays, respectively. Results: Among the 32 participants (low dose, n=12; high dose, n=12; placebo, n=8) no serious adverse events or adverse events leading to study treatment discontinuation were observed. Treatment-emergent adverse events considered to be related to the study drug occurred in 37.5% of the participants in the placebo group and 62.5% in the PRV-101 group (injection site pain, headache, injection site discomfort and injection site pruritus being most common). PRV-101 induced dose-dependent neutralising antibody responses against all five CVB serotypes included in the vaccine in both the high- and low-dose groups. Protective titres ≥8 against all five serotypes were seen in >90% of participants over the entire follow-up period. Conclusions/interpretation: The results indicate that the tested multivalent CVB vaccine is well tolerated and immunogenic, supporting its further clinical development. Trial registration: ClinicalTrials.gov NCT04690426. Funding: This trial was funded by Provention Bio, a Sanofi company. Graphical

8 November 2025 in Diabetologia
Verified
Journal Article
Open access
PDF file
SKSalla Kuusela
Salla Kuusela
JKJaakko J. Koskenniemi
Jaakko J. Koskenniemi
TVToni Valtanen
Toni Valtanen
TPTytti Pokka
Tytti Pokka
THTaina Härkönen
Taina Härkönen
RVRiitta Veijola
Riitta Veijola
Aims/hypothesis: Islet autoimmunity during presymptomatic type 1 diabetes is heterogeneous. We hypothesised that a positive family history of type 1 diabetes is associated with specific characteristics of the autoimmune process resulting in clinical diabetes. In a prospective birth cohort study, we compared the initiation and evolution of islet autoimmunity and the rate of progression from islet autoimmunity to diabetes between children with and without a first-degree relative (FDR) with type 1 diabetes. Methods: In the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study, we prospectively followed children with HLA-conferred susceptibility from birth for the appearance of islet autoantibodies (IAA, GADA, IA-2A, ZnT8A), further development of islet autoimmunity, and progression to clinical diabetes. The presence of type 1 diabetes among their FDRs was recorded at the time of birth, and the family history data was updated during the follow-up period. Results: Among a total of 1334 children with confirmed positivity for at least one islet autoantibody, 145 (10.9%) had one or more FDRs with type 1 diabetes at the time of birth (FDR+). During a median follow-up period of 8.6 years, FDRs of an additional 87 children developed type 1 diabetes (FDR− FDR+). At seroconversion, both FDR+ and FDR− FDR+ children were significantly more often positive for GADA and multiple autoantibodies than children without affected FDRs (FDR−). The seroconversion age was similar between the three groups (median 2.7 vs 2.1 vs 3.0 years in FDR+, FDR− FDR+ and FDR− children, respectively). During the follow-up period, FDR+ and FDR− FDR+ children more often had IAA, GADA, IA-2A and multiple autoantibodies than FDR− children, and progressed more frequently to diabetes (55.9 vs 57.5 vs 38.9%, respectively). Time from seroconversion to clinical diabetes was significantly shorter in FDR+ children compared with FDR− children (2.7 vs 3.6 years). Children with paternal type 1 diabetes at birth ( n =71; i.e., the father had type 1 diabetes) were twice as often positive for multiple autoantibodies at seroconversion as those with maternal type 1 diabetes ( n =50; i.e. the mother had type 1 diabetes) (39.4% vs 20.0%). Conclusions/interpretation: At seroconversion, genetically susceptible children who had one or more FDRs with type 1 diabetes, especially an affected father, were more often positive for GADA and multiple islet autoantibodies. During the follow-up period, children with an affected FDR were more often positive for IAA, GADA and IA-2A, and progressed to clinical type 1 diabetes more often and faster than children without an affected FDR. These data should be considered when designing intervention and screening studies. Graphical

11 December 2023 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
AKAnni Kyrönniemi
Anni Kyrönniemi
TVToni Valtanen
Toni Valtanen
JKJaakko Koskenniemi
Jaakko Koskenniemi
PVPaula Vähäsalo
Paula Vähäsalo
THTaina Härkönen
Taina Härkönen
RVRiitta Veijola
Riitta Veijola
Objective. We studied the characteristics of children who developed islet autoantibodies by the age of 0.50 years and hypothesized that the appearance of extremely early islet autoimmunity differs between four birth cohorts within 1994–2019 according to the change in the incidence of Type 1 diabetes (T1D) in Finland. Methods. Data from Finnish children participating in the Type 1 Diabetes Prediction and Prevention (DIPP) study, or the Environmental Determinants of Diabetes in the Young (TEDDY) study were analyzed. These studies follow children with increased HLA-conferred risk for T1D with regular measurements of islet autoantibodies. Maternally transferred antibodies were excluded by comparing islet autoantibodies in cord serum, child’s first follow-up serum and the maternal serum. Results. Among 20,979 Finnish children at increased risk to T1D, 53 (0.25%) developed at least one islet autoantibody at the age of ≤0.50 years. During a mean follow-up of 8.1 years, 15.1% progressed to T1D (median age at diagnosis 2.0 years), 43.4% developed confirmed islet autoimmunity but no T1D, and 41.5% had only transient islet autoantibodies. IAA was the most common first-appearing autoantibody. Among progressors, age at diagnosis was 1.0–2.4 years in children with IAA-initiated autoimmunity and 4.5–16.1 years in ZnT8A-initiated autoimmunity. When comparing children developing autoantibodies either at the age of ≤0.50 years or 0.51–0.75 years, confirmed positivity during follow-up was more common in the older group (81.7% vs. 58.5%; ). In four birth cohorts within 1994–2019 appearance of islet autoantibodies at the age of ≤0.50 years decreased towards the most recent birth cohorts ( ). Conclusion. Islet autoimmunity by the age of 0.50 years was rare in genetically susceptible children and was typically initiated with IAA. Confirmed positivity was less common in children with autoantibodies at age ≤0.50 than at slightly older age. The secular decrease of islet autoimmunity before age 0.50 years was observed. This trial is registered with NCT03269084 and NCT00279318.

20 November 2024 in HLA
Verified
Journal Article
Open access
ATAntti‐Mathias Taka
Antti‐Mathias Taka
THTaina Härkönen
Taina Härkönen
PVPaula Vähäsalo
Paula Vähäsalo
Tommi VatanenTommi Vatanen
Tommi Vatanen
JLJohanna Lempainen
Johanna Lempainen
TRThe Finnish Pediatric Diabetes Register
The Finnish Pediatric Diabetes Register
We set out to examine in an observational study characteristics of type 1 diabetes at the time of diagnosis among paediatric patients carrying the protective HLA class II DQB1*06:02 allele. We compared characteristics of type 1 diabetes among 5530 Finnish children aged 0–14 years diagnosed between 2003 and 2018. Seventy‐five children with type 1 diabetes carried the DQB1*06:02 allele. The carriers of DQB1*06:02 allele were compared to all children with type 1 diabetes without this allele and those with a high‐risk genotype. We also analysed, how does the genotype of a high‐risk haplotype paired with DQB1*06:02 affect the phenotype of patients with newly diagnosed type 1 diabetes. Carriers of the DQB1*06:02 allele were diagnosed at an older age than those with any other HLA class II genotype (p = 0.003) or the high‐risk genotype (p < 0.001). After adjusting the results for age and sex, no significant differences in clinical markers were observed. Glutamic acid decarboxylase autoantibody (GADA) levels were higher among carriers of DQB1*06:02 when compared to those with other genotypes (p = 0.033). Having a high‐risk haplotype paired with DQB1*06:02‐positive haplotype was associated with higher levels of islet antigen 2 autoantibodies (IA‐2A) (p < 0.001) and somewhat shorter duration of symptoms (p = 0.043). The association between the protective DQB1*06:02 allele and an older age at diagnosis as well as higher levels of GADA at diagnosis of type 1 diabetes was confirmed. The effects of the DQB1*06:02‐positive haplotype seem to dominate when paired with a high‐risk haplotype.